Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells

Yang,Jinxing; Huang,Hanwen; Xiao,Dan; Duan,Yang; Zheng,Yanfang; Chen,Zhong

doi:10.3892/ijo.2021.5195

Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells

Authors:
- Jinxing Yang
- Hanwen Huang
- Dan Xiao
- Yang Duan
- Yanfang Zheng
- Zhong Chen
View Affiliations

Affiliations: Department of Orthopedic Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China, Department of Spinal Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China, Department of Spine Surgery, Orthopedics Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China, Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
Published online on: March 3, 2021 https://doi.org/10.3892/ijo.2021.5195
Article Number: 15
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chordoma is a rare low‑grade tumor of the axial skeleton. Over previous decades, a range of targeted drugs have been used for treating chordoma, with more specific and effective therapies under investigation. Transmembrane Emp24 protein transport domain containing 3 (TMED3) is a novel gene reported to be a regulator of oncogenesis, cancer development and metastasis; however, its role in chordoma remains unclear. In the present study, the expression of TMED3 was investigated in chordoma cells, and the effect of TMED3 knockdown on chordoma development was examined in vitro and in vivo, followed by exploration of differentially expressed proteins in TMED3‑silenced chordoma cells via an apoptosis antibody array. Reverse transcription‑quantitative PCR and western blot assays were performed to determine the expression levels. It was revealed that TMED3 was highly expressed in chordoma, and that knockdown of TMED3 inhibited cell viability and migration, and enhanced the apoptosis of chordoma cells. Additionally, knockdown of TMED3 inhibited the expression of Bcl‑2, heat shock protein 27, insulin‑like growth factor (IGF)‑I, IGF‑II, IGF binding protein‑2, Livin, Akt, CDK6 and cyclin D1 proteins, whereas MAPK9 was upregulated. Furthermore, a xenograft nude mice model demonstrated that TMED3 expression promoted tumor growth. Collectively, the present findings suggested that knockdown of TMED3 inhibited cell viability and migration, and enhanced apoptosis in chordoma cells, and that TMED3 may be a novel target for chordoma therapy.

View Figures

View References

1	Sahyouni R, Goshtasbi K, Mahmoodi A and Chen JW: A historical recount of chordoma. J Neurosurg Spine. 28:422–428. 2018. View Article : Google Scholar : PubMed/NCBI
2	Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ and Duan Z: Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol. 15:1002212019. View Article : Google Scholar : PubMed/NCBI
3	Stacchiotti S and Sommer J; Chordoma Global Consensus Group: Building a global consensus approach to chordoma: A position paper from the medical and patient community. Lancet Oncol. 16:e71–e83. 2015. View Article : Google Scholar : PubMed/NCBI
4	Guan JY, He XF, Chen Y, Zeng QL, Mei QL and Li YH: Percutaneous intratumoral injection with pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococcygeal chordomas. J Vasc Interv Radiol. 22:1216–1220. 2011. View Article : Google Scholar : PubMed/NCBI
5	Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S and Briggs TW: A review of the surgical management of sacral chordoma. Eur J Surg Oncol. 40:1412–1420. 2014. View Article : Google Scholar : PubMed/NCBI
6	Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ: T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 41:1176–1178. 2009. View Article : Google Scholar : PubMed/NCBI
7	Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, et al: Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 24:1931–1936. 2013. View Article : Google Scholar : PubMed/NCBI
8	Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, et al: Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury. Mol Cancer Ther. 17:603–613. 2018. View Article : Google Scholar
9	Strating JR and Martens GJ: The p24 family and selective transport processes at the ER-Golgi interface. Biol Cell. 101:495–509. 2009. View Article : Google Scholar : PubMed/NCBI
10	Barr FA, Preisinger C, Kopajtich R and Korner R: Golgi matrix proteins interact with p24 cargo receptors and aid their efficient retention in the Golgi apparatus. J Cell Biol. 155:885–891. 2001. View Article : Google Scholar : PubMed/NCBI
11	Connolly DJ, O'Neill LA and McGettrick AF: The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J Biol Chem. 288:5616–5623. 2013. View Article : Google Scholar : PubMed/NCBI
12	Peng C, Huang K, Liu G, Li Y and Yu C: MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3. J Gastroenterol Hepatol. 34:1711–1719. 2019. View Article : Google Scholar : PubMed/NCBI
13	Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z and Wang B: TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p. Cancer Cell Int. 19:752019. View Article : Google Scholar : PubMed/NCBI
14	Ha M, Moon H, Choi D, Kang W, Kim JH, Lee KJ, Park D, Kang CD, Oh SO, Han ME, et al: Prognostic role of TMED3 in clear cell renal cell carcinoma: A retrospective Multi-cohort analysis. Front Genet. 10:3552019. View Article : Google Scholar :
15	Zheng H, Yang Y, Han J, Jiang WH, Chen C, Wang MC, Gao R, Li S, Tian T, Wang J, et al: TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep. 6:370702016. View Article : Google Scholar : PubMed/NCBI
16	Vainio P, Mpindi JP, Kohonen P, Fey V, Mirtti T, Alanen KA, Perälä M, Kallioniemi O and Iljin K: High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One. 7:e398012012. View Article : Google Scholar : PubMed/NCBI
17	Mishra S, Bernal C, Silvano M, Anand S and Ruiz IAA: The protein secretion modulator TMED9 drives CNIH4/TGFalpha/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases. Oncogene. 38:5817–5837. 2019. View Article : Google Scholar : PubMed/NCBI
18	Duquet A, Melotti A, Mishra S, Malerba M, Seth C, Conod A and Altaba AR: A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol Med. 6:882–901. 2014. View Article : Google Scholar : PubMed/NCBI
19	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Laferriere CA and Pang DS: Review of intraperitoneal injection of sodium pentobarbital as a method of euthanasia in laboratory rodents. J Am Assoc Lab Anim Sci. 59:254–263. 2020. View Article : Google Scholar : PubMed/NCBI
22	National Research Council (US) Committee for the Update of the Guide for the Care and se of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press (US); Washington, DC: 2011
23	Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal HA, Alm T, Asplund A, Björk L, Breckels LM, et al: A subcellular map of the human proteome. Science. 356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
24	Aber R, Chan W, Mugisha S and Jerome-Majewska LA: Transmembrane emp24 domain proteins in development and disease. Genet Res (Camb). 101:e142019. View Article : Google Scholar
25	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
26	Brahmkhatri VP, Prasanna C and Atreya HS: Insulin-like growth factor system in cancer: Novel targeted therapies. Biomed Res Int. 2015:5380192015. View Article : Google Scholar : PubMed/NCBI
27	Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U and Bogenrieder T: Insulin-like growth factor (IGF) pathway targeting in cancer: Role of the IGF axis and opportunities for future combination studies. Target Oncol. 12:571–597. 2017. View Article : Google Scholar : PubMed/NCBI
28	Bach LA: IGF-binding proteins. J Mol Endocrinol. 61:T11–T28. 2018. View Article : Google Scholar
29	Baxter RC: IGF binding proteins in cancer: Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341. 2014. View Article : Google Scholar : PubMed/NCBI
30	Kasof GM and Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 276:3238–3246. 2001. View Article : Google Scholar
31	Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A and Kroemer G: HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. Cell Cycle. 2:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
32	Deveraux QL, Schendel SL and Reed JC: Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin. 19:57–74. 2001. View Article : Google Scholar
33	Kandel ES and Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 253:210–229. 1999. View Article : Google Scholar : PubMed/NCBI
34	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
35	Hoxhaj G and Manning BD: The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 20:74–88. 2020. View Article : Google Scholar :
36	Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, et al: Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol. 12:776–789. 2010. View Article : Google Scholar : PubMed/NCBI
37	Fry MJ: Phosphoinositide 3-kinase signalling in breast cancer: How big a role might it play? Breast Cancer Res. 3:304–312. 2001. View Article : Google Scholar : PubMed/NCBI
38	Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, et al: Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol. 21:1401–1411. 2019. View Article : Google Scholar : PubMed/NCBI
39	Sherr CJ, Beach D and Shapiro GI: Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6:353–367. 2016. View Article : Google Scholar :
40	Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:957–972. 1997. View Article : Google Scholar : PubMed/NCBI
41	Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S, Hwang SG, Kang SG, Suh Y, Park MJ and Lee SJ: c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene. 31:4655–4666. 2012. View Article : Google Scholar : PubMed/NCBI
42	Bubici C and Papa S: JNK signalling in cancer: In need of new, smarter therapeutic targets. Br J Pharmacol. 171:24–37. 2014. View Article : Google Scholar :
43	Wu Q, Wu W, Fu B, Shi L, Wang X and Kuca K: JNK signaling in cancer cell survival. Med Res Rev. 39:2082–2104. 2019. View Article : Google Scholar : PubMed/NCBI
44	Sabapathy K and Wagner EF: JNK2: A negative regulator of cellular proliferation. Cell Cycle. 3:1520–1523. 2004. View Article : Google Scholar : PubMed/NCBI
45	Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA and Chambers TC: Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem. 275:29980–29985. 2000. View Article : Google Scholar : PubMed/NCBI